FDA approves first targeted genetic therapy for advanced pancreatic cancer

The FDA has authorized a new treatment for advanced pancreatic cancer that specifically targets a genetic mutation, marking a shift from traditional chemotherapy. While the drug demonstrates life-extending capabilities, its long-term efficacy in broader patient populations remains to be established in clinical practice.